Barclays
FBLG icon

Barclays’s FibroBiologics FBLG Stock Holding History

Barclays’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– – – 5515
2025
Q4 		– Hold
0
– – – 5771
2025
Q3 		– Hold
0
– – – 5454
2025
Q2 		– Sell
-1,486
Closed -$26.8K – 5207
2025
Q1 		$26.7K Sell
1,486
-679
-31% -$19.4K ﹤0.01% 4747
2024
Q4 		$86.6K Buy
2,165
+167
+8% +$8.96K ﹤0.01% 4629
2024
Q3 		$123K Buy
1,998
+1,567
+364% +$104K ﹤0.01% 4514
2024
Q2 		$43K Buy
+431
New +$82.2K ﹤0.01% 4261

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Barclays's FBLG Position: Q1 2026 in Review

Barclays held its FibroBiologics (FBLG) position steady in Q1 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5515.

Barclays first reported a position in FBLG in Q2 2024 and has held it in 4 quarters since. The position peaked at $123K in Q3 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Barclays held 0 shares of FibroBiologics worth $0 as of Q1 2026.
  • Barclays left its FibroBiologics share count unchanged in Q1 2026.
  • FibroBiologics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #5515 holding.
  • Barclays first reported a position in FibroBiologics in Q2 2024 and has held it in 4 quarters since.
  • Barclays's FibroBiologics position peaked at $123K in Q3 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.